Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

BACKGROUND: Rifampin is a key drug in antituberculosis chemotherapy because it rapidly kills the majority of bacilli in tuberculosis lesions, prevents relapse and thus enables 6-month short-course chemotherapy. Little is known about the pharmacokinetics of rifampin in children. The objective of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaaf, Hendrik Simon, Willemse, Marianne, Cilliers, Karien, Labadarios, Demetre, Maritz, Johannes Stephanus, Hussey, Gregory D, McIlleron, Helen, Smith, Peter, Donald, Peter Roderick
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679060/
https://www.ncbi.nlm.nih.gov/pubmed/19386087
http://dx.doi.org/10.1186/1741-7015-7-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679060/
https://www.ncbi.nlm.nih.gov/pubmed/19386087
http://dx.doi.org/10.1186/1741-7015-7-19

Ejemplares similares